PRM143 - Improvements in Patient-Reported outcomes Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study

Autor: Emery, P, Bingham, C, Burmester, G, Bykerk, V, Furst, D, Mariette, X, Purcaru, O, Coteur, G, Vanlunen, B, Weinblatt, M
Zdroj: In Value in Health November 2015 18(7):A707-A708
Databáze: ScienceDirect
Externí odkaz: